This inventor holds 1 USPTO granted patent. Top assignee: Abbott Laboratories Corporation. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Walid M Abi-Saab: Innovator in ADHD Treatment
Introduction
Walid M Abi-Saab is a notable inventor based in Dornach, Switzerland. He has made significant contributions to the field of pharmacology, particularly in the treatment of attention-deficit/hyperactivity disorder (ADHD). His innovative work has led to the development of compounds that target nicotinic receptors, offering new hope for individuals affected by this condition.
Latest Patents
Abi-Saab holds a patent for a treatment specifically designed for ADHD. The patent, titled "3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof," describes effective nicotinic receptor agonist compounds. These compounds have demonstrated a pharmacological effect for alleviating symptoms associated with ADHD. He has 1 patent to his name, showcasing his innovative approach to addressing this prevalent disorder.
Career Highlights
Walid M Abi-Saab is associated with Abbott Laboratories Corporation, a leading global healthcare company. His work at Abbott has allowed him to collaborate with other experts in the field and contribute to advancements in medical treatments. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Abi-Saab has worked alongside notable colleagues, including Tushar S Garimella and Earle E Bain. These collaborations have fostered an environment of innovation and have led to significant advancements in the treatment of ADHD.
Conclusion
Walid M Abi-Saab's contributions to ADHD treatment through his patented innovations highlight his role as a leading inventor in the pharmaceutical field. His work continues to impact the lives of many individuals affected by this disorder.